Driehaus Capital ARQT Position
Active6-Fund ConvergenceDriehaus Capital increased their position in Arcus Biosciences Inc. (ARQT) in Q4 2025, holding $74.4M worth of shares across 2,562,445 shares.
The position was first reported in Q4 2024 and has been tracked across 5 quarterly 13F filings.
ARQT is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Domvanalimab in 75 days (Jun 30, 2026), making the timing of Driehaus's position particularly relevant.
Short interest stands at 15.6% of float with 11.3 days to cover, indicating significant bearish positioning against Driehaus's long thesis.
About Arcus Biosciences Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Full company profile →Short Interest
15.6%
11.3 days to cover
Driehaus Capital ARQT Position History
Frequently Asked Questions
Does Driehaus Capital own ARQT?
Yes. As of Q4 2025, Driehaus Capital holds 2,562,445 shares of Arcus Biosciences Inc. (ARQT) valued at $74.4M. This data comes from their SEC 13F filing.
How many hedge funds own ARQT?
6 specialist biotech hedge funds currently hold ARQT, including Cormorant Asset Management, OrbiMed Advisors, Perceptive Advisors and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy ARQT?
Driehaus Capital's position in ARQT was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's ARQT position increasing or decreasing?
Driehaus Capital increased their ARQT position in the most recent quarter, adding 1,465,441 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ARQTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →